Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about ALLOGENE THERAPEUTICS, INC.
01/26Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Confere..
GL
01/18Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H..
AQ
01/14INSIDER BUY : Allogene Therapeutics
MT
01/12Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11ALLOGENE THERAPEUTICS : JPM Presentation 2022
PU
01/11Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences
MT
01/11Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini..
AQ
01/11Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical ..
AQ
01/11US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy
MT
01/11Antion Biosciences SA announced that it expects to receive funding from Allogene Therap..
CI
01/10Allogene Therapeutics' T Cell Trials Off FDA Clinical Hold
MT
01/10ALLOGENE : FDA Lifts Clinical Hold Across AlloCAR T Studies
DJ
01/10Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T&trade..
AQ
01/10Allogene Therapeutics, Inc. Announces U.S. Food and Drug Administration Removes Clinica..
CI
01/04Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conf..
AQ
01/03Guggenheim Adjusts Price Target for Allogene Therapeutics to $35 From $40, Maintains Bu..
MT
2021ALLOGENE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events (fo..
AQ
2021Allogene Therapeutics Expands San Francisco Headquarters; Shares Rise Early
MT
2021Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innov..
AQ
2021Allogene Therapeutics, Inc. Enters Into Lease Agreement to Expand its Headquarters in S..
CI
2021Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgki..
AQ
2021Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single D..
AQ
2021RBC Cuts Price Target on Allogene Therapeutics to $35 From $45 Amid 'Mixed' Data, Keeps..
MT
2021ALLOGENE THERAPEUTICS : ASH 2021 Conference Call Presentation
PU
2021Allogene Says ALLO-501, ALLO-501A Show Potential in Updated Early-Stage Data
MT
2021Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single D..
AQ
2021Allogene Therapeutics, Inc. Reports Positive Results from Phase 1 Universal Study of Si..
CI
2021Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgki..
AQ
2021Allogene Therapeutics, Inc. Reports Positive Phase 1 Data from ALPHA Trials in Non-Hodg..
CI
2021Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL P..
GL
2021ALLOGENE THERAPEUTICS : Corporate Presentation - November 2021
PU
2021Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Confere..
GL
2021Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Confere..
GL
2021Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
AQ
2021Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update ..
PU
2021ALLOGENE THERAPEUTICS : Q3 Earnings Snapshot
AQ
2021ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
2021Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Updateá..
AQ
2021Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
AQ
2021Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
CI
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allog..
PR
2021Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
GL
2021ALLOGENE THERAPEUTICS : Cowen Starts Allogene Therapeutics at Outperform
MT
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allog..
PR
2021Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
2021Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
2021ALLOGENE THERAPEUTICS : JMP Securities Adjusts Allogene Therapeutics' Price Target to $27 ..
MT
2021ALLOGENE THERAPEUTICS : SMBC Nikko Initiates Coverage on Allogene Therapeutics With Outper..
MT
2021AFTER HOURS WATCH LIST SCORECARD : Vxrt, agrx, allo
MT
2021Occidental Petroleum, Chubb rise; Allogene, Oshkosh fall
AQ
2021ALLOGENE THERAPEUTICS' : Stock Slump After FDA Clinical Hold on CAR T Cell Therapy Offers ..
MT
2021Health Care Limping in Late Trade
MT
2021Top Midday Decliners
MT
2021Health Care Stocks Limping Toward Weekend
MT
2021ALLOGENE THERAPEUTICS : Roth Capital Adjusts Allogene Therapeutics PT to $35 From $60, Mai..
MT
2021ALLOGENE THERAPEUTICS : Shares Plunge After FDA Halts Cell Therapy Trial But Clinical Hold..
MT
2021ALLOGENE THERAPEUTICS : Oppenheimer Adjusts Allogene Therapeutics PT to $40 From $44, Main..
MT
2021ALLOGENE THERAPEUTICS : Price Target Cut by Oppenheimer After FDA Places Clinical Hold on ..
MT
2021Wall Street Wavers Pre-Bell as US Jobs Growth Misses Expectations
MT
2021Health Care Stocks Mixed Pre-Bell Friday
MT
2021Top Premarket Decliners
MT
2021ALLOGENE THERAPEUTICS : B. Riley Lowers Price Target on Allogene Therapeutics to $30 From ..
MT
2021ALLOGENE THERAPEUTICS : Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Pa..
AQ
2021ALLOGENE THERAPEUTICS : Stifel Downgrades Allogene Therapeutics to Hold from Buy, Adjusts ..
MT
2021ALLOGENE THERAPEUTICS : Goldman Sachs Downgrades Allogene Therapeutics to Neutral from Buy..
MT
2021ALLOGENE THERAPEUTICS : RBC Cuts Price Target on Allogene Therapeutics to $45 From $55 Ami..
MT
2021ALLOGENE THERAPEUTICS : Says FDA Places Clinical Hold on ALLO-501A Study Over Chromosomal ..
MT
2021Allogene Therapeutics Drops Premarket After FDA Puts Hold on Study
DJ
2021MT NEWSWIRES AFTER HOURS WATCH LIST : Vxrt, agrx, allo
MT
2021ALLOGENE THERAPEUTICS : Says FDA Places Clinical Hold on ALLO-501A Study Over Chromosomal ..
MT
2021ALLOGENE THERAPEUTICS : Says FDA Placed Clinical Hold on ALLO-501A Study Over Chromosomal ..
MT
2021ALLOGENE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2021ALLOGENE THERAPEUTICS : Reports FDA Clinical Holdáof AlloCAR T Trials Based on a Single Pa..
GL
1  2  3  4  5Next
Upcoming event on ALLOGENE THERAPEUTICS, INC.